Mounting Data Support Combination Atezolizumab/Bevacizumab As a New First-Line Standard of Care in Advanced HCC

2020 ◽  
Keyword(s):  
Standard Of Care ◽  
First Line ◽  
Advanced Hcc ◽  
Data Support ◽  
Line Standard

scholarly journals ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

2021 ◽  
Author(s):  
Thorsten Fuereder
Keyword(s):  
Head And Neck Cancer ◽  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Standard Of Care ◽  
Treatment Intensification ◽  
First Line ◽  
Open Questions ◽  
Virtual Meeting ◽  
Metastatic Setting ◽  
Line Standard

SummaryDuring the ASCO 2021 virtual meeting, multiple clinically relevant studies were presented addressing open questions regarding the therapy of nasopharyngeal carcinomas (NPC): Is immunotherapy plus chemotherapy the new first line standard of care for patients in the recurrent/metastatic setting? Is adjuvant therapy with capecitabine in high risk NPC patients post chemoradiation (CRT) beneficial? Is there a role for treatment intensification by adjuvant metronomic capecitabine in NPC patients post induction chemotherapy and CRT? This article summarizes the most significant NPC studies presented at the ASCO 2021 virtual meeting and discusses the data in the context of the current literature.

scholarly journals Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy

2020 ◽  
Vol 9 (Suppl. 1) ◽  
pp. 31-39
Author(s):  
Terry J. Smith
Keyword(s):  
Paradigm Shift ◽  
Vision Loss ◽  
Standard Of Care ◽  
Autoimmune Process ◽  
First Line ◽  
Thyroid Associated Ophthalmopathy ◽  
The Us ◽  
Fundamental Research ◽  
Line Standard

<b><i>Background:</i></b> Thyroid-associated ophthalmopathy (TAO), an autoimmune process affecting the tissues surrounding the eye, most commonly develops in individuals with Graves’ disease. It is disfiguring, can cause vision loss, and dramatically lessens the quality of life in patients. There has been an absence of approved medical therapies for TAO with proven effectiveness and safety in multicenter, placebo-controlled, and adequately powered clinical trials. <b><i>Summary:</i></b> The following is a brief overview of the rationale for developing a monoclonal antibody inhibitor of the insulin-like growth factor-I receptor into a treatment for TAO. This area of fundamental research has yielded an effective and safe medication, namely teprotumumab, based on two multicenter, placebo-controlled trials. Teprotumumab, marketed as Tepezza, has been approved recently by the US Food and Drug Administration for the treatment of TAO. Given its remarkable effectiveness, Tepezza is poised to become the first-line standard of care for TAO. <b><i>Key Messages:</i></b> Introduction of Tepezza into our armamentarium of therapeutic strategies for TAO represents a paradigm shift in the management of the disease. I proffer that the drug will replace glucocorticoids as a first-line treatment for TAO.

Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1023-1023 ◽  
Author(s):  
Ander Urruticoechea ◽  
Seock-Ah Im ◽  
Montserrat Munoz ◽  
Jose Baselga ◽  
Denise A. Yardley ◽  
...  
Keyword(s):  
Metastatic Breast ◽  
Standard Of Care ◽  
Phase Iii ◽  
Clinical Activity ◽  
Limited Data ◽  
First Line ◽  
Previously Treated ◽  
Phase Iii Studies ◽  
Line Standard ◽  
Clinical Trial Information

1023 Background: T-DM1 was approved for pts with HER2+ MBC previously treated with trastuzumab (H) and a taxane based on the phase III EMILIA study. P in combination with H + docetaxel (T) later became the first-line standard of care for HER2+ MBC, but there are limited data on T-DM1 efficacy in pts who previously received P. We present exploratory efficacy results from pts treated with T-DM1 any time after P from 2 phase III studies: CLEOPATRA and PHEREXA. Methods: CLEOPATRA (NCT00567190) and PHEREXA (NCT01026142) are randomized, 2-arm trials evaluating P-based regimens for HER2+ MBC. CLEOPATRA studies H + T + P vs HT + placebo in pts with no prior anti-HER2 treatment (tx) or chemotherapy for MBC, while PHEREXA studies H + capecitabine (C) +/− P in pts who progressed during/after previous H tx for MBC. We assessed overall survival (OS) in an exploratory analysis of pts who either received or did not receive T-DM1 at any time after discontinuing study-assigned tx in CLEOPATRA or PHEREXA. Results: Of 408 pts who received HTP in CLEOPATRA and 228 pts who received HCP in PHEREXA, 32 and 43 pts received subsequent T-DM1, respectively (Table). Median duration of T-DM1 tx was 7.1 mo (range 0−44) and 4.2 mo (range 0−22), respectively, and median time from discontinuation of P to start of T-DM1 was 3.5 mo (range 1−47) and 10.6 mo (range 1−28). Conclusions: Although data are limited in these exploratory analyses, our results provide additional evidence of T-DM1 clinical activity in pts with HER2+ MBC who progressed on prior P + H, a finding with real-world implications. Clinical trial information: NCT00567190, NCT01026142. [Table: see text]

scholarly journals PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC

2016 ◽  
Vol 11 (11) ◽  
pp. S307 ◽  
Author(s):  
George Blumenschein ◽  
Jason Chandler ◽  
Edward B. Garon ◽  
David Waterhouse ◽  
Jonathan W. Goldman ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Phase 1 ◽  
Standard Of Care ◽  
First Line ◽  
Line Standard
Sign in / Sign up

Export Citation Format

Share Document